Montréal, Canada – April 17, 2008 -- TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced that the company will participate in three upcoming medical conferences in the next two months. These conferences include the SMi Asthma and COPD Therapeutics Conference, the RNAi World Congress 2008, and the American Thoracic Society’s 2008 International Conference.

Presentation Information

The SMi Asthma and COPD Therapeutics Conference will take place from April 23-24, 2008 at the Copthorne Tara Hotel, London, U.K. Mark Parry-Billings, Ph.D., Chief Development Officer at TOPIGEN and Chairman of the conference, will present, “Application of Antisense Oligonucleotides in Asthma and COPD,” on April 23, 2008 at 3:30 PM. For more information, please visit http://www.smi-online.co.uk/events/overview.asp?is=4&ref=2868

The RNAi World Congress 2008 will take place in Boston, MA from April 30–May 2, 2008 at the Boston Logan Hilton. Nicolay Ferrari, Ph.D., Director, Pharmacology at TOPIGEN, will present “FANA-Modified Nucleic Acids as Versatile RNA-Targeting Agents,” on April 30, 2008 at 2:30 PM as part of the RNAi Therapeutics (Session 1). For more information, please visit http://www.selectbiosciences.com/conferences/RNAiWC2008/

TOPIGEN News

The American Thoracic Society’s 2008 International Conference will take place from May 16-21, 2008 in Toronto, Ontario, Canada. Topigen will have poster presentations of two abstracts, #1359 (Session Code C44) “TPI 1100: an inhaled antisense oligonucleotide (AON) against Phosphodiesterase (PDE) 4 and 7 with significant anti-inflammatory effects in a mouse model for COPD,” presented by Marylène Fortin, Ph.D., Research Scientist, and #917 (Session Code 832) “Pre-clinical efficacy of TPI 2200: a third generation multi-target antisense oligonucleotide treatment for asthma,” presented by Hélène D’Anjou, Ph.D., Research Scientist. For more information, please visit http://www.thoracic.org/sections/meetings-and-courses/international-conference/2008/index.html

About TOPIGEN

TOPIGEN is a privately held, clinical-stage company focused on developing new classes of inhaled drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. TOPIGEN is actively progressing two drug candidates in Phase 2 trials for COPD and asthma, including TPI 1020, a novel anti-inflammatory, licensed from NicOx S.A. and TPI ASM8, which utilizes its proprietary mRNA-silencing technology. These drug candidates target multiple pathways and pro-inflammatory mediators involved in chronic pulmonary diseases.

Current venture investors include NovaQuest, MMV Financial, Inc., BDC Venture Capital, Fonds de solidarité FTQ, Desjardins Venture Capital, Caisse de Dépot et Placement du Québec (Caisse), T2C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR. For more detailed information on TOPIGEN visit www.topigen.com.